Home / Science / Viagra's Key Ingredient Offers Hope for Rare Childhood Disease
Viagra's Key Ingredient Offers Hope for Rare Childhood Disease
4 Apr
Summary
- Sildenafil, the active compound in Viagra, is being tested for Leigh syndrome.
- The drug improved symptoms in children with the rare, fatal genetic disease.
- A Europe-wide clinical trial is planned to further evaluate sildenafil's efficacy.
A promising new avenue for treating Leigh syndrome, a rare and deadly genetic childhood disease, has emerged with the investigation of sildenafil. This compound, known for its role in erectile dysfunction medication, has demonstrated the potential to alleviate symptoms in affected children. Early findings indicate improvements in muscle strength and neurological functions.
Researchers observed that sildenafil treatment, administered in doses significantly lower than those found in Viagra, led to enhanced motor skills and suppressed critical metabolic crises and seizures in some patients. The positive results from initial studies on human patients, lab-grown tissues, and animals are encouraging.
These developments offer a crucial glimmer of hope, as Leigh syndrome affects approximately one in 36,000 children globally, with half dying before the age of three. Currently, no approved treatments exist for this progressive condition. A comprehensive, Europe-wide clinical trial is now being planned to further validate sildenafil's effectiveness and safety.
The research team, including scientists from Charité's Universitätsmedizin in Berlin, is optimistic about finding a viable drug candidate. They note that improved blood flow, a known effect of sildenafil, might be key to treating complications like high blood pressure in the lungs associated with Leigh syndrome.
